AMRN Amarin Corp

    RNS Number : 9952X
  Amarin Corporation Plc
  01 July 2008
   
      Amarin Corporation plc ("Amarin" or the "Company")
    


    DUBLIN, Ireland, July 1, 2008 - Amarin Corporation plc ("Amarin" or the "Company") announces that it intends to send its Annual Report
for the year ended 31 December, 2007 together with notice of its 2008 AGM to shareholders on July 7,  2008. 

    About Amarin
    Amarin is a biopharmaceutical company focused on improving the lives of patients suffering from cardiovascular and central nervous
system (CNS) diseases. Amarin's cardiovascular programs capitalize on the known therapeutic benefits of essential fatty acids in
cardiovascular disease. Amarin's CNS development pipeline includes programs in myasthenia gravis, Huntington's disease, Parkinson's disease,
epilepsy and memory. Amarin also has two proprietary technology platforms: a lipid-based technology platform for the targeted transport of
molecules through the liver and/or to the brain, and a unique mRNA technology based on cholinergic neuromodulation. Amarin has its primary
stock market listing in the U.S. on the NASDAQ Capital Market ("AMRN").


    Contacts: 
    Amarin +353 (0)1 669 9020 
    Thomas Lynch, Chairman and Chief Executive Officer
    Alan Cooke, President and Chief Operating Officer
    Darren Cunningham, EVP Strategic Development and Investor Relations
    investor.relations@amarincorp.com 







    This announcement has been issued through the Companies Announcement Service of
    the Irish Stock Exchange.



This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
ISEFKDKQCBKKFOK

Amarin (LSE:AMRN)
Gráfico Histórico do Ativo
De Jan 2025 até Fev 2025

Amarin (LSE:AMRN)
Gráfico Histórico do Ativo
De Fev 2024 até Fev 2025